Logo image
Back
Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen
Journal article   Peer reviewed

Clopidogrel therapy in patients undergoing coronary stenting: value of a high-loading-dose regimen

Jürgen Pache, Adnan Kastrati, Julinda Mehilli, Meinrad Gawaz, Franz-Josef Neumann, Melchior Seyfarth, Donald Hall, Siegmund Braun, Josef Dirschinger and Albert Schömig
Catheterization and cardiovascular interventions, v 55(4), pp 436-441
Apr 2002
DOI: https://doi.org/10.1002/ccd.10092
PMID: 11948888
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Blood Vessel Prosthesis Implantation Coronary Angiography Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - drug therapy Coronary Artery Disease - surgery Dose-Response Relationship, Drug Drug Therapy, Combination Female Humans Immunoglobulin Fab Fragments - administration & dosage Immunoglobulin Fab Fragments - therapeutic use Male Middle Aged Platelet Aggregation Inhibitors - administration & dosage Platelet Aggregation Inhibitors - therapeutic use Platelet Glycoprotein GPIIb-IIIa Complex - administration & dosage Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors Platelet Glycoprotein GPIIb-IIIa Complex - therapeutic use Preoperative Care Stents Ticlopidine - administration & dosage Ticlopidine - analogs & derivatives Ticlopidine - therapeutic use
The objective of this study was to assess the value of a clopidogrel regimen based on a high loading dose initiated before the stent placement procedure. A consecutive series of 864 patients treated with a high-loading-dose clopidogrel regimen (600 mg given 2-4 hr prior to intervention) was compared with 870 patients treated with conventional ticlopidine therapy. Abciximab was given periprocedurally in 62% of the patients. The composite endpoint of death, myocardial infarction, or urgent revascularization was reached by 39 (4.5%) clopidogrel patients and 59 (6.8%) ticlopidine patients. Clopidogrel therapy was associated with a 35% reduction of the risk for early adverse events (odds ratio 0.65; 95% confidence interval, 0.43-0.98). Thus, a high-loading-dose clopidogrel regimen in patients undergoing coronary artery stenting was safe and led to a more favorable clinical outcome than conventional therapy with ticlopidine regardless of concomitant treatment with abciximab.

Metrics

4 Record Views
45 citations in Web of Science
61 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Cardiac & Cardiovascular Systems
Logo image